Table 2.
Summary of HLA molecules bound by vaccinia virus epitopes
| Ligand | Sequence | MAb useda | Molecule detection resultb |
|||
|---|---|---|---|---|---|---|
| HLA-A2 | HLA-B27 | HLA-B51 | HLA-Cw1 | |||
| A17L9-17 | MLDDFSAGA | PA2.1 | +c | ND | ND | ND |
| A10L614-623 | SPEGEETII | PA2.1 | + | ND | ND | ND |
| A10L688-696 | ILDRIITNA | PA2.1 | + | ND | ND | ND |
| A10L867-876 | SRGYFEHMKK | ME1 | ND | + | ND | ND |
| B8R53-59 | WQTMYTN | ME1 | ND | + | ND | ND |
| K2L16-30 | YRLQGFTNAGIVAYK | ME1/W6-32 | − | + | − | + |
| D5R148-157 | IAMKRTLLEL | W6-32 | − | ND | + | − |
| A50R294-301 | LPFGSLGI | W6-32 | − | ND | + | − |
| C11R101-110 | IPSPGIMLV | W6-32 | − | ND | + | + |
| A17L9-25 | MLDDFSAGAGVLDKDL | W6-32 | − | ND | − | + |
| D8L112-119 | DGLIIISI | W6-32 | − | ND | − | + |
a
The MAbs used for the sequential immunoprecipitations were PA2.1 (specific for HLA-A2), ME1 (specific for HLA-B27), and W6-32 (specific for a monomorphic HLA-A, HLA-B, or HLA-C determinant).
b
ND, not done.
c
Significant difference (P < 0.001) compared with the negative control results.